CardioGenics Holdings Inc., incorporated on December 16, 1997, is a development-stage company. The Company develops technology and products targeting the immunoassay segment of the in vitro diagnostic (IVD) testing market. Its CardioGenics products include QL Care Analyzer (QLCA), Cardiovascular Tests and Paramagnetic Beads. The QLCA represents a shift in the design of point-of-care (POC) analyzers. The QLCA is a small, portable, stand-alone and completely automated point-of-care immunoassay analyzer. The Company has developed four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. The Company has developed a process that coats the beads with a layer of silver, making them white, and more sensitive to light.
|Headquarters||Unit 8, 6295 Northam Drive|
MISSISSAUGA, ON, Canada L4V 1W8
|Acting Independent Chairman of the Board||J.Neil Tabatznik|
|Chief Executive Officer, Director||Yahia Gawad|
|Chief Financial Officer||James Essex|
|Corporate Secretary, Director||Linda Sterling|
|Independent Director||Alexander Reid|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P Capital IQ, INK and Argus.
|Shares Out.||36.0M||Book Value||$0.00|
|CardioGenics Holdings Inc does not pay a dividend.||P/E||--|
|P/Cash Flow (TTM)||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.